PDB: 2356 resultsInfo pagesStatus searchChemie searchBIRD

---

3A4O	Lyn kinase domain Descriptor: STAUROSPORINE, Tyrosine-protein kinase Lyn Authors: Miyano, N, Kinoshita, T, Tada, T. Deposit date: 2009-07-11 Release date: 2009-12-08 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (3 Å) Cite: Structural basis for the inhibitor recognition of human Lyn kinase domain Bioorg.Med.Chem.Lett., 19, 2009
3AD5	Crystal structure of Triazolone derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394) Descriptor: (4S)-2-METHYL-2,4-PENTANEDIOL, 4-[4-(benzyloxy)phenyl]-5-{[2-(4-chlorophenyl)-2-oxoethyl]sulfanyl}-2,4-dihydro-3H-1,2,4-triazol-3-one, DIMETHYL SULFOXIDE, ... Authors: Tsuji, E. Deposit date: 2010-01-14 Release date: 2011-01-19 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2 Å) Cite: Ab initio fragment molecular orbital study of ligand binding to leukocyte-specific protein tyrosine (LCK) kinase To be Published
6J6M	Co-crystal structure of BTK kinase domain with Zanubrutinib Descriptor: (7S)-2-(4-phenoxyphenyl)-7-(1-propanoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, IMIDAZOLE, Tyrosine-protein kinase BTK Authors: Zhou, X, Hong, Y. Deposit date: 2019-01-15 Release date: 2019-10-23 Last modified: 2023-11-22 Method: X-RAY DIFFRACTION (1.25 Å) Cite: Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. J.Med.Chem., 62, 2019
7JYS	hALK in complex with 3-(3-chlorophenyl)-5-methyl-1H-pyrazole Descriptor: 1,2-ETHANEDIOL, 3-(3-chlorophenyl)-5-methyl-1H-pyrazole, ALK tyrosine kinase receptor Authors: McGrath, A.P, Zou, H, Lane, W, Saikatendu, K. Deposit date: 2020-08-31 Release date: 2021-01-20 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (2.22 Å) Cite: Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design. Acs Omega, 5, 2020
6GQQ	Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 35) Descriptor: Vascular endothelial growth factor receptor 2, ~{N}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(4-propan-2-yl-1,2,3-triazol-1-yl)ethanamide Authors: Schimpl, M, Hardy, C.J, Ogg, D.J, Overman, R.C, Packer, M.J, Kettle, J.G, Anjum, R, Barry, E, Bhavsar, D, Brown, C, Campbell, A, Goldberg, K, Grondine, M, Guichard, S, Hunt, T, Jones, O, Li, X, Moleva, O, Pearson, S, Shao, W, Smith, A, Smith, J, Stead, D, Stokes, S, Tucker, M, Ye, Y. Deposit date: 2018-06-07 Release date: 2018-09-19 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (1.52 Å) Cite: Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J. Med. Chem., 61, 2018
2YIY	Crystal structure of compound 8 bound to TAK1-TAB Descriptor: (1E)-1-[5-TERT-BUTYL-2-(3-FLUOROPHENYL)-1H-PYRAZOL-3-YLIDENE]-3-(4-PYRIDIN-3-YLOXYPHENYL)UREA, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 Authors: Brown, D.G, Phillips, C. Deposit date: 2011-05-17 Release date: 2012-05-23 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (2.49 Å) Cite: The Discovery and Synthesis of Selective Dfg-Out Tak-1 Inhibitors To be Published
6HD4	ABL1 IN COMPLEX WITH COMPOUND 7 AND IMATINIB (STI-571) Descriptor: 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, CHLORIDE ION, ... Authors: Cowan-Jacob, S.W. Deposit date: 2018-08-17 Release date: 2018-10-24 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (2.03 Å) Cite: Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J. Med. Chem., 61, 2018
6HES	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT050 Descriptor: 1,2-ETHANEDIOL, 4-methyl-3-[(2-pyridin-3-ylquinazolin-4-yl)amino]-~{N}-[3-(trifluoromethyl)phenyl]benzamide, Ephrin type-A receptor 2 Authors: Kudlinzki, D, Troester, A, Witt, K, Linhard, V.L, Gande, S.L, Saxena, K, Schwalbe, H. Deposit date: 2018-08-20 Release date: 2019-08-28 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (1.128 Å) Cite: Effects of NVP-BHG712 chemical modifications on EPHA2 binding and affinity To Be Published
6HEX	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATMM006 Descriptor: 4-methyl-3-[(1-methyl-6-pyrazin-2-yl-pyrazolo[3,4-d]pyrimidin-4-yl)amino]-~{N}-[3-(trifluoromethyl)phenyl]benzamide, Ephrin type-A receptor 2 Authors: Kudlinzki, D, Troester, A, Witt, K, Linhard, V.L, Gande, S.L, Saxena, K, Schwalbe, H. Deposit date: 2018-08-20 Release date: 2019-08-28 Last modified: 2024-01-17 Method: X-RAY DIFFRACTION (1.413 Å) Cite: Effects of NVP-BHG712 chemical modifications on EPHA2 binding and affinity To Be Published
6HRP	CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4-dihydroisoquinolin-1-one Descriptor: 6-~{tert}-butyl-8-fluoranyl-2-[2-(hydroxymethyl)-3-[1-methyl-5-[(5-morpholin-4-ylcarbonylpyridin-2-yl)amino]-6-oxidanylidene-pyridazin-3-yl]phenyl]phthalazin-1-one, Tyrosine-protein kinase BTK Authors: Janson, C, Kuglstatter, A. Deposit date: 2018-09-28 Release date: 2019-03-20 Last modified: 2024-05-15 Method: X-RAY DIFFRACTION (1.12 Å) Cite: A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation. Bioorg.Med.Chem.Lett., 29, 2019
3BCE	Crystal structure of the ErbB4 kinase Descriptor: DI(HYDROXYETHYL)ETHER, MANGANESE (II) ION, Receptor tyrosine-protein kinase erbB-4, ... Authors: Qiu, C. Deposit date: 2007-11-12 Release date: 2008-02-12 Last modified: 2024-02-21 Method: X-RAY DIFFRACTION (2.5 Å) Cite: Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase. Structure, 16, 2008
7KPL	Crystal structure of hEphB1 in apo form Descriptor: Ephrin type-B receptor 1 Authors: Ahmed, M, Wang, P, Sadek, H. Deposit date: 2020-11-11 Release date: 2021-03-10 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2.705 Å) Cite: Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain. Proc.Natl.Acad.Sci.USA, 118, 2021
7KPM	Crystal structure of hEphB1 bound with ADP Descriptor: ADENOSINE-5'-DIPHOSPHATE, Ephrin type-B receptor 1 Authors: Ahmed, M, Wang, P, Sadek, H. Deposit date: 2020-11-11 Release date: 2021-03-10 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (1.608 Å) Cite: Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain. Proc.Natl.Acad.Sci.USA, 118, 2021
7JYT	hALK in complex with 3-(3-methyl-1H-pyrazol-5-yl)pyridine Descriptor: 3-(3-methyl-1H-pyrazol-5-yl)pyridine, ALK tyrosine kinase receptor, GLYCEROL Authors: McGrath, A.P, Zou, H, Lane, W, Saikatendu, K. Deposit date: 2020-08-31 Release date: 2021-01-20 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (2 Å) Cite: Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design. Acs Omega, 5, 2020
2YJS	Structure of C1156Y Mutant Anaplastic Lymphoma Kinase Descriptor: ALK TYROSINE KINASE RECEPTOR Authors: McTigue, M, Deng, Y, Liu, W, Brooun, A. Deposit date: 2011-05-23 Release date: 2012-06-06 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (1.9 Å) Cite: Structure of C1156Y Mutant Anaplastic Lymphoma Kinase To be Published
2YN8	ephB4 kinase domain inhibitor complex Descriptor: EPHRIN TYPE-B RECEPTOR 4, STAUROSPORINE Authors: Read, J, Brassington, C.A, Overmann, R. Deposit date: 2012-10-13 Release date: 2013-10-23 Last modified: 2024-05-08 Method: X-RAY DIFFRACTION (2.11 Å) Cite: Stability and Solubility Engineering of the Ephb4 Tyrosine Kinase Catalytic Domain Using a Rationally Designed Synthetic Library. Protein Eng.Des.Sel., 26, 2013
7JY4	hALK in complex with ((1S,2S)-1-(2,4-difluorophenyl)-2-(2-(3-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenoxy)cyclopropyl)methanamine Descriptor: 1-{(1S,2S)-1-(2,4-difluorophenyl)-2-[2-(3-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenoxy]cyclopropyl}methanamine, ALK tyrosine kinase receptor Authors: McGrath, A.P, Zou, H, Lane, W, Saikatendu, K. Deposit date: 2020-08-28 Release date: 2021-01-20 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (2.42 Å) Cite: Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design. Acs Omega, 5, 2020
3B8Q	Crystal structure of the VEGFR2 kinase domain in complex with a naphthamide inhibitor Descriptor: N-(4-chlorophenyl)-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide, Vascular endothelial growth factor receptor 2 Authors: Whittington, D.A, Long, A.M, Gu, Y, Zhao, H. Deposit date: 2007-11-01 Release date: 2008-04-01 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2.75 Å) Cite: Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis and Evaluation J.Med.Chem., 51, 2008
3B2T	Structure of phosphotransferase Descriptor: 5'-O-[(S)-hydroxy{[(S)-hydroxy(methyl)phosphoryl]oxy}phosphoryl]adenosine, Fibroblast growth factor receptor 2, PHOSPHATE ION Authors: Lew, E.D, Bae, J.H, Rohmann, E, Wollnik, B, Schlessinger, J. Deposit date: 2007-10-19 Release date: 2008-02-26 Last modified: 2023-08-30 Method: X-RAY DIFFRACTION (1.8 Å) Cite: Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. Proc.Natl.Acad.Sci.Usa, 104, 2007
3BEA	cFMS tyrosine kinase (tie2 KID) in complex with a pyrimidinopyridone inhibitor Descriptor: 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]phenyl}amino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide, Macrophage colony-stimulating factor 1 receptor, SULFATE ION Authors: Schubert, C. Deposit date: 2007-11-16 Release date: 2008-07-15 Last modified: 2023-08-30 Method: X-RAY DIFFRACTION (2.02 Å) Cite: Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors. Bioorg.Med.Chem.Lett., 18, 2008
7JU6	Structure of RET protein tyrosine kinase in complex with selpercatinib Descriptor: FORMIC ACID, Proto-oncogene tyrosine-protein kinase receptor Ret, Selpercatinib Authors: Terzyan, S.S, Shen, T, Wu, J, Mooers, B.H.M. Deposit date: 2020-08-19 Release date: 2020-11-11 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (2.06 Å) Cite: Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol, 32, 2021
3BBW	crystal structure of the ErbB4 kinase in its inactive conformation Descriptor: Receptor tyrosine-protein kinase erbB-4 Authors: Qiu, C. Deposit date: 2007-11-11 Release date: 2008-02-12 Last modified: 2024-02-21 Method: X-RAY DIFFRACTION (4 Å) Cite: Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase. Structure, 16, 2008
6HMX	RIP2 Kinase Catalytic Domain complex with N(4,5dimethyl1Hpyrazol3yl)7methoxy6(2methylpropane2sulfonyl)quinolin4amine Descriptor: 6-~{tert}-butylsulfonyl-~{N}-(3,4-dimethyl-1~{H}-pyrazol-5-yl)-7-methoxy-quinolin-4-amine, Receptor-interacting serine/threonine-protein kinase 2 Authors: Convery, M.A, Haile, P.A. Deposit date: 2018-09-13 Release date: 2018-11-07 Last modified: 2024-05-15 Method: X-RAY DIFFRACTION (2.53 Å) Cite: Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel. ACS Med Chem Lett, 9, 2018
2Z8C	Phosphorylated insulin receptor tyrosine kinase in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin-2-yl]amino}phenyl)acetic acid Descriptor: 6-mer peptide from Insulin receptor substrate 1, Insulin receptor, [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Authors: Katayama, N, Kurihara, H. Deposit date: 2007-09-05 Release date: 2008-08-12 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (3.25 Å) Cite: Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors. Proteins, 73, 2008
2ZV7	Lyn Tyrosine Kinase Domain, apo form Descriptor: Tyrosine-protein kinase Lyn Authors: Williams, N.K, Rossjohn, J. Deposit date: 2008-11-04 Release date: 2008-11-11 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (2.5 Å) Cite: Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State J.Biol.Chem., 284, 2009

<48495051525354555657585960616263>